Spero Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Spero Therapeutics, Inc. (SPRO) reported Earnings Per Share, Basic and Diluted of -$1.01 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-16
- Spero Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.01.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.90.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.70.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.63.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$2.91.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$3.52.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$3.35.
- Spero Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$2.60.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$1.01 10-Q · filed 2022-05-16 | -$1.91 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.61 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$3.26 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.90 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.61 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.24 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.91 10-K · filed 2022-03-31 |
| 2021-09-30 | -$0.70 10-Q · filed 2021-11-10 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.99 10-Q · filed 2021-11-10 | -$2.67 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$0.63 10-Q · filed 2021-08-05 | -$1.29 10-Q · filed 2021-08-05 | -$1.96 derived: net income ÷ weighted average shares · filed 2022-08-10 | -$2.79 derived: net income ÷ weighted average shares · filed 2022-08-10 |
| 2021-03-31 | -$0.66 10-Q · filed 2022-05-16 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-05-16 | -$2.17 derived: net income ÷ weighted average shares · filed 2022-05-16 | -$3.00 derived: net income ÷ weighted average shares · filed 2022-05-16 |
| 2020-12-31 | -$0.68 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.52 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$2.36 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$3.52 10-K · filed 2022-03-31 |
| 2020-09-30 | -$0.86 10-Q · filed 2021-11-10 | -$1.71 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.91 10-Q · filed 2021-11-10 | -$4.20 derived: net income ÷ weighted average shares · filed 2021-11-10 |
| 2020-06-30 | -$0.85 10-Q · filed 2021-08-05 | -$2.06 10-Q · filed 2021-08-05 | -$3.36 derived: net income ÷ weighted average shares · filed 2021-08-05 | -$4.31 derived: net income ÷ weighted average shares · filed 2021-08-05 |
| 2020-03-31 | -$1.22 10-Q · filed 2021-05-06 | -$2.53 derived: net income ÷ weighted average shares · filed 2021-05-06 | -$3.48 derived: net income ÷ weighted average shares · filed 2021-05-06 | -$4.25 derived: net income ÷ weighted average shares · filed 2021-05-06 |
| 2019-12-31 | -$1.31 10-K · filed 2020-03-16 | -$2.26 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$3.03 derived: net income ÷ weighted average shares · filed 2021-03-11 | -$3.35 10-K · filed 2021-03-11 |
| 2019-09-30 | -$0.95 10-Q · filed 2020-11-05 | -$1.70 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$2.01 10-Q · filed 2020-11-05 | -$2.61 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2019-06-30 | -$0.74 10-Q · filed 2020-08-06 | -$1.04 10-Q · filed 2020-08-06 | -$1.64 derived: net income ÷ weighted average shares · filed 2020-08-06 | -$2.24 derived: net income ÷ weighted average shares · filed 2020-08-06 |
| 2019-03-31 | -$0.29 10-Q · filed 2020-05-08 | -$0.90 derived: net income ÷ weighted average shares · filed 2020-05-08 | -$1.50 derived: net income ÷ weighted average shares · filed 2020-05-08 | -$2.16 derived: net income ÷ weighted average shares · filed 2020-05-08 |
| 2018-12-31 | -$0.60 10-K · filed 2020-03-16 | -$1.20 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$1.88 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$2.60 10-K · filed 2020-03-16 |
| 2018-09-30 | -$0.60 10-K · filed 2020-03-16 | -$1.28 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$2.01 10-Q · filed 2019-11-04 | -$3.30 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2018-06-30 | -$0.69 10-K · filed 2020-03-16 | -$1.43 10-Q · filed 2019-08-08 | -$2.79 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$4.95 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2018-03-31 | -$0.74 10-K · filed 2020-03-16 | -$2.15 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$4.69 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$8.16 derived: net income ÷ weighted average shares · filed 2020-03-16 |
| 2017-12-31 | -$1.59 10-K · filed 2019-03-14 | -$5.59 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$11.76 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$17.82 10-K · filed 2019-03-14 |
| 2017-09-30 | -$36.02 10-K · filed 2019-03-14 | -$72.22 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$93.96 10-Q · filed 2018-11-08 | -$119.76 derived: net income ÷ weighted average shares · filed 2019-03-14 |
| 2017-06-30 | -$36.21 10-K · filed 2019-03-14 | -$57.88 10-Q · filed 2018-08-09 | -$83.64 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$106.99 derived: net income ÷ weighted average shares · filed 2019-03-14 |
| 2017-03-31 | -$21.60 10-K · filed 2019-03-14 | -$47.24 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$70.48 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$95.73 derived: net income ÷ weighted average shares · filed 2019-03-14 |
| 2016-12-31 | -$25.68 10-K · filed 2018-04-02 | -$48.93 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$74.21 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$95.87 10-K · filed 2019-03-14 |
| 2016-09-30 | -$23.23 10-K · filed 2018-04-02 | -$48.51 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$70.15 10-Q · filed 2017-12-14 | |
| 2016-06-30 | -$25.30 10-K · filed 2018-04-02 | -$46.95 derived: net income ÷ weighted average shares · filed 2018-04-02 | ||
| 2016-03-31 | -$21.51 10-K · filed 2018-04-02 | |||
| 2015-12-31 | -$53.11 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |